FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 719 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... February 17, 2025 Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... August 18, 2020 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... June 13, 2025 Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests May 23, 2018 Load more HOT NEWS How targeted screening can help the NHS save lives from lung... Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... ESMO Calls for Cancer to Remain a Flagship Priority in the... Wine Racks and the Mystery of Survival
